

## Palopegteriparatide

Cat. No.:	HY-P10277	
CAS No.:	2222514-07-8	
Sequence:	{X}-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (X= O-methylpolyethylene glycol (2 x 20 kDa mPEG)-Aib)	{X}-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe (X= O-methylpolyethylene glycol (2 x 20 kDa mPEG)-Aib)
Sequence Shortening:	{X}-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF (X= O-methylpolyethylene glycol (2 x 20 kDa mPEG)-Aib)	
Target:	Others	
Pathway:	Others	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

### BIOLOGICAL ACTIVITY

#### Description

Palopegteriparatide (Transcon PTH) is a long-acting parathyroid hormone (PTH) prodrug that can maintain normal and stable calcium concentrations without the need for calcium and active vitamin D replacement. Palopegteriparatide can be used in the research of hypoparathyroidism<sup>[1][2]</sup>.

### REFERENCES

[1]. Khan AA, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. *J Bone Miner Res.* 2023;38(1):14-25.

[2]. Kontogeorgos G. Parathyroid Hormone Hyper-and Hypoparathyroidism Effect of Treatment and Long-term Follow-up Studies[M]. 2024.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA